Biogen wins Tecfidera patent challenge from Mylan, sending shares way up

Biogen investors have been on a wild ride over the last year, and on Wednesday they experienced their first major jolt in 2020. It was a welcome one.

The company prevailed in a high-stakes patent challenge from Mylan, giving Biogen a win as it continues defending its big-selling multiple sclerosis drug Tecfidera from would-be copycats.